HSP90AA1 and neoplasm: Using clinical parameters that were associated with poor clinical outcome, such as tumor size, grade, nodal status, age, HER2, ER and RP status, we demonstrated that high-level expressions of HSP90AA1 and HSP90AB1 were independent poor prognosis factors affecting triple-negative and HER2-/ER+ breast cancer subtypes.